It’s developing products for glaucoma and other conditions.

NEW YORK — Biopharmaceutical company Eyenovia Inc. has closed on an initial public offering of 2.73 million shares of common stock.

Eyenovia received $27.3 million in gross proceeds from the offering, according to a press release. The company's common shares are traded on the Nasdaq Capital Market under the ticker symbol "EYEN."

Eyenovia is "a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye," according to the release.

Eyenovia’s pipeline is focused on micro-therapeutics for glaucoma and other eye diseases. The company's website says its technology "will replace outdated dropper technology for improved patient experience and compliance."

This story is tagged under:
SPONSORED VIDEO: VISION SOURCE

Optometric Practice in a Small Town

Practicing in a small town gives you the diversity and opportunities to practice full-scope optometry. See how one OD found professional and personal fulfillment in a small town.

INVISIONMAG ON INSTAGRAM

Promoted Headlines